About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and fluorouracil‑based chemotherapy for adults with metastatic colorectal cancer carrying a ...
The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more ...
Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results